PhaseBio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 09 2020 - 4:05PM
Business Wire
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel therapies for cardiovascular and
cardiopulmonary diseases, today announced that Chief Executive
Officer Jonathan P. Mow will present a company overview at the
upcoming H.C. Wainwright 22nd Annual Global Investment Conference
on Tuesday, September 15, at 12:00 p.m. EDT.
The event will be available via live webcast from the “Events
and Presentations” page of the “Investors” section of the company’s
website at www.phasebio.com. The webcast replay will be available
for 90 days after the conclusion of the live presentation.
About PhaseBio
PhaseBio Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel therapies for cardiovascular and
cardiopulmonary diseases. The company’s pipeline includes: PB2452,
a novel reversal agent for the antiplatelet therapy ticagrelor;
PB1046, a once-weekly vasoactive intestinal peptide receptor
agonist for the treatment of pulmonary arterial hypertension and
hospitalized COVID-19 patients at high risk for rapid clinical
deterioration and ARDS; and PB6440, an oral agent for the treatment
of resistant hypertension. PhaseBio’s proprietary elastin-like
polypeptide technology platform enables the development of
therapies with potential for less-frequent dosing and improved
pharmacokinetics, including PB1046, and drives both internal and
partnership drug-development opportunities.
PhaseBio is located in Malvern, PA, and San Diego, CA. For more
information, please visit www.phasebio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200909006016/en/
Investor Contact: John Sharp PhaseBio Pharmaceuticals,
Inc. Chief Financial Officer (610) 981-6506
john.sharp@phasebio.com
Media Contact: Will Zasadny Canale Communications, Inc.
will@canalecomm.com 619-961-8848
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Mar 2024 to Apr 2024
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Apr 2023 to Apr 2024